Cision PR Newswire

AvenCell Therapeutics Announces IND Clearance and EMA Approval of Clinical Trial Application (CTA) for the QUADvance Study, a Phase I/II trial evaluating AVC-203, a Novel Allogeneic CD19/CD20 CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-cell malignancies

CAMBRIDGE, Mass., Dec. 4, 2025 /PRNewswire/ — AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both switchable... Read more.
Press Release
Back to top button